Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (1427)	4/20/2002 12:16:25 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1477

Correct..... one should have multiple molecules, relying on DIFFERENT chemistries, in development for each target. It is glib to talk about how great your molecule is, this early in testing. Nonetheless, there's always the GOOD luck element as well, and...... well, good luck in this case could represent "first to 5 billion market". In terms of the accomplishment..... SCIO is one of the very oldest of biotechs, having started life as California Biotechnology. They should have those multiple molecules against a single target and much, much more. The current management team is not to blame. However, they aren't allowed glib, either. :-) disclosure... no position, just watching as one of biotech's perennial disappointments turns it around.... watching with admiration.